proxyvotesnow.com

Home › Companies › VENTYX BIOSCIENCES INC. › 2023-2024

VENTYX BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and VENTYX BIOSCIENCES INC.’s Form 8-K, filed 2024-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 135Asset managers
  • 914Fund votes
  • 2024-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VENTYX BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VENTYX BIOSCIENCES INC.

These tallies are VENTYX BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VENTYX BIOSCIENCES INC. — official shareholder meeting results, meeting held 2024-06-05
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Onaiza Cadoret-Manier, M.B.A. 32,008,430---- 10,875,15914,526,548 Majority: yes
Elect Director: Allison Hulme, Ph.D. 42,643,275---- 250,37114,516,491 Majority: yes
Proposal 2: Advisory Vote on Executive Compensation. The "say-on-pay" proposal regarding the compensation of our named executive officers as described on page 21 of the Proxy Statement was approved, on an advisory basis. 32,870,21710,004,89818,529 --14,516,493 Majority: yes
Proposal 4: Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following 56,542,563119,328748,246 ---- Majority: yes

Source: VENTYX BIOSCIENCES INC., Form 8-K, filed with the SEC on 2024-06-06 — read the filing on EDGAR.

How asset managers voted at the VENTYX BIOSCIENCES INC. 2023-2024 meeting

Each item below shows how the 135 asset managers that disclosed a VENTYX BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VENTYX BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2023 Summary Compensation Table in the "Executive Compensation" section of the proxy statement (the "Say-on-Pay Vote").

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%AGAINST 23%
FOR: 32,870,217AGAINST: 10,004,898

VENTYX BIOSCIENCES INC.’s own tally for this item (“Proposal 2: Advisory Vote on Executive Compensation. The "say-on-pay" proposal regarding the compensation of our named executive officers as described on page 21 of the Proxy Statement was approved, on an advisory basis.”): 32,870,217 for, 10,004,898 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 70,499,332 outstanding shares: 46.6% for, 14% against (61% of the company cast a for/against vote).

The 135 asset managers below cast 73% of the shares they voted on this item FOR (24,678,087 for, 8,954,820 against).

FOR 73%AGAINST 27%
FOR: 24,678,087 (73.4%)AGAINST: 8,954,820 (26.6%)ABSTAIN: 1,787 (0.0%)NOT VOTED: 1,375 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the named executive officers identified in the 2023 Summ” at VENTYX BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)3,665,4850 00For
Capital Group7,6193,123,232 00Against
BlackRock2,603,6080 00For
Vanguard2,333,1160 00For
Redmile Group, LLC02,164,126 00Against
ORBIMED ADVISORS LLC01,870,456 00Against
Citadel1,682,8990 00For
Octagon Capital Advisors LP1,501,1140 00For
Cormorant Asset Management, LP1,420,0000 00For
Fidelity1,318,9540 00For
JPMorgan1,249,8470 00For
Opaleye Management Inc.1,245,0000 00For
Point721,213,4360 00For
State Street882,602299 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.772,1360 00For
Charles Schwab0770,310 00Against
GEODE CAPITAL MANAGEMENT, LLC678,1780 00For
Delaware/Macquarie430,0000 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST430,0000 00For
Northern Trust393,87856 00For
FARALLON CAPITAL MANAGEMENT LLC0380,000 00Against
Connor, Clark & Lunn Investment Management Ltd.286,6870 00For
MUTUAL FUND SERIES TRUST202,5000 00For
MELLON INVESTMENTS Corp198,3350 00For
Invesco0196,135 00Against

Showing the 25 largest of 135 asset managers. See all 135 in the interactive database.

2. To approve, on an advisory basis, the frequency of future Say-on-Pay Votes.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 56%1 YEAR 41%

The 130 asset managers below cast 100% of the shares they voted on this item FOR (732,368 for, 0 against).

FOR: 732,368 (2.4%)ONE YEAR: 17,407,625 (56.2%)1 YEAR: 12,827,745 (41.4%)THREE YEARS: 9,201 (0.0%)UNKNOWN: 2,254 (0.0%)NOT VOTED: 1,375 (0.0%)3 YEARS: 305 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the frequency of future Say-on-Pay Votes.” at VENTYX BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)00 001 Year
Capital Group00 00One Year
BlackRock00 00One Year
Vanguard00 00One Year
Redmile Group, LLC00 001 Year
ORBIMED ADVISORS LLC00 001 Year
Citadel00 00One Year
Octagon Capital Advisors LP00 001 Year
Cormorant Asset Management, LP00 001 Year
Fidelity00 00One Year
Point7200 00One Year
State Street00 00One Year
Charles Schwab00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
JPMorgan1000 001 Year
Delaware/Macquarie00 00One Year
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST00 00One Year
Northern Trust00 001 Year
FARALLON CAPITAL MANAGEMENT LLC380,0000 00For
Connor, Clark & Lunn Investment Management Ltd.00 00One Year
MUTUAL FUND SERIES TRUST202,5000 00For
MELLON INVESTMENTS Corp00 00One Year
Invesco00 00One Year
Voya00 00One Year
DE Shaw00 00One Year

Showing the 25 largest of 130 asset managers. See all 130 in the interactive database.

3. To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Allison Hulme, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 42,643,275WITHHELD: 250,371

VENTYX BIOSCIENCES INC.’s own tally for this item (“Elect Director: Allison Hulme, Ph.D.”): 42,643,275 for, 250,371 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 70,499,332 outstanding shares: 60% for, 0.4% withheld (61% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (8,328,843 for, 0 against).

FOR 99.0%
FOR: 8,328,843 (99.1%)ABSTAIN: 77,584 (0.9%)
Largest asset managers voting on “To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and until their ” at VENTYX BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,314,1900 00For
Capital Group1,561,6160 00For
BlackRock1,065,7880 00For
Fidelity966,7940 00For
JPMorgan525,5580 00For
Delaware/Macquarie430,0000 00For
Charles Schwab385,1550 00For
MUTUAL FUND SERIES TRUST202,5000 00For
Equitable61,1630 73,5300Abstain
TIAA132,6560 00For
Lincoln Financial117,0270 1,0060For
Voya93,4690 00For
QUANTITATIVE MASTER SERIES LLC91,7310 00For
Invesco88,1410 00For
New York Life45,5080 00For
Brighthouse41,7900 00For
AIG/SunAmerica23,0640 00For
T. Rowe Price21,3960 00For
Northern Trust21,1350 00For
State Street18,7380 00For
John Hancock17,1810 00For
Pacific Life15,1150 00For
Nationwide13,0600 00For
SEI9,3000 00For
Bridge Builder Trust8,7110 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 56,542,563AGAINST: 119,328

VENTYX BIOSCIENCES INC.’s own tally for this item (“Proposal 4: Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, ”): 56,542,563 for, 119,328 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 70,499,332 outstanding shares: 80% for, 0.2% against (80% of the company cast a for/against vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (8,406,427 for, 0 against).

FOR 100%
FOR: 8,406,427 (100.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at VENTYX BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,314,1900 00For
Capital Group1,561,6160 00For
BlackRock1,065,7880 00For
Fidelity966,7940 00For
JPMorgan525,5580 00For
Delaware/Macquarie430,0000 00For
Charles Schwab385,1550 00For
MUTUAL FUND SERIES TRUST202,5000 00For
Equitable134,6930 00For
TIAA132,6560 00For
Lincoln Financial118,0330 00For
Voya93,4690 00For
QUANTITATIVE MASTER SERIES LLC91,7310 00For
Invesco88,1410 00For
New York Life45,5080 00For
Brighthouse41,7900 00For
AIG/SunAmerica23,0640 00For
T. Rowe Price21,3960 00For
Northern Trust21,1350 00For
State Street18,7380 00For
John Hancock17,1810 00For
Pacific Life15,1150 00For
Nationwide13,0600 00For
SEI9,3000 00For
Bridge Builder Trust8,7110 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Onaiza Cadoret Manier, M.B.A.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%
FOR: 32,008,430WITHHELD: 10,875,159

VENTYX BIOSCIENCES INC.’s own tally for this item (“Elect Director: Onaiza Cadoret-Manier, M.B.A.”): 32,008,430 for, 10,875,159 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 70,499,332 outstanding shares: 45.4% for, 15% withheld (61% of the company cast a for/withheld vote).

The 40 asset managers below cast 100% of the shares they voted on this item FOR (7,145,036 for, 0 against).

FOR 87%13%
FOR: 7,145,036 (87.1%)ABSTAIN: 1,058,891 (12.9%)
Largest asset managers voting on “To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and until their ” at VENTYX BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,300,5900 13,6000For
Capital Group1,561,6160 00For
BlackRock1,065,7880 00For
Fidelity962,7940 4,0000For
JPMorgan525,5580 00For
Delaware/Macquarie00 430,0000Abstain
Charles Schwab385,1550 00For
Equitable61,1630 73,5300Abstain
TIAA00 132,6560Abstain
Lincoln Financial100,2400 17,7930For
Voya00 93,4690Abstain
QUANTITATIVE MASTER SERIES LLC91,7310 00For
Invesco00 88,1410Abstain
New York Life00 45,5080Abstain
Brighthouse00 41,7900Abstain
AIG/SunAmerica00 23,0640Abstain
T. Rowe Price21,3960 00For
Northern Trust21,1350 00For
State Street18,7380 00For
John Hancock00 17,1810Abstain
Pacific Life15,1150 00For
Nationwide00 13,0600Abstain
SEI00 9,3000Abstain
Bridge Builder Trust8,7110 00For
ProShares00 8,0240Abstain

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

6. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 54.8%ONE YEAR 45.2%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 772,136 (54.8%)ONE YEAR: 636,522 (45.2%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at VENTYX BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.00 001-Year
JPMorgan00 00One Year

Largest VENTYX BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked by the number of VENTYX BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 70,499,332 shares outstanding at the time of that meeting.

Top VENTYX BIOSCIENCES INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5.20%
2Capital Group 4.44%
3BlackRock 3.69%
4Vanguard 3.31%
5Redmile Group, LLC 3.07%
6ORBIMED ADVISORS LLC 2.65%
7Citadel 2.39%
8Octagon Capital Advisors LP 2.13%
9Cormorant Asset Management, LP 2.01%
10Fidelity 1.87%

Reported VENTYX BIOSCIENCES INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VENTYX BIOSCIENCES INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Somasundaram Subramaniam, M.B.A. 12.02% DEF14A
Entities affiliated with New Science Ventures 11.97% DEF14A
S 9.53% 13G
Citadel Advisors 8.47% 13F
Entities affiliated with Citadel Advisors LLC 6.07% DEF14A
Vanguard Group 5.35% 13F
Cormorant Global Healthcare Master Fund, LP 5.21% DEF14A
Deerfield Partners, L.P. 5.02% DEF14A
Point72 3.59% 13F
Raju Mohan, Ph.D. 3.56% DEF14A

Percentages above are of 70,499,332 shares outstanding, as reported by VENTYX BIOSCIENCES INC. on its Form 10-Q dated 2024-05-06 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VENTYX BIOSCIENCES INC.’s 10-Q dated 2024-05-06. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VENTYX BIOSCIENCES INC.'s shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 135 asset managers reported how they voted in their SEC Form N-PX filings, covering 914 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the named executive officers identified… — FOR was 77% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VENTYX BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-06.

VENTYX BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.